Advertisement

Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial

      Abstract

      Background and purpose

      Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL).

      Material and methods

      Men with low and intermediate-risk prostate cancer were randomly assigned to 40 Gy in 5 fractions delivered once per week (QW) vs. every other day (EOD). QOL was assessed using the Expanded Prostate Cancer Index Composite. The primary endpoint was the proportion with a minimum clinically important change (MCIC) in bowel QOL during the acute (≤12 week) period, and analysis was by intention-to-treat. ClinicalTrials.gov NCT01423474.

      Results

      152 men from 3 centres were randomized with median follow-up of 47 months. Patients treated QW had superior acute bowel QOL with 47/69 (68%) reporting a MCIC compared to 63/70 (90%) treated EOD (p = 0.002). Fewer patients treated QW reported moderate–severe problems with bowel QOL during the acute period compared with EOD (14/70 [20%] vs. 40/70 [57%], p < 0.001). Acute urinary QOL was also better in the QW arm, with 52/67 (78%) vs 65/69 (94%) experiencing a MCIC (p = 0.006). There were no significant differences in late urinary or bowel QOL at 2 years or last follow-up.

      Conclusion

      Prostate SBRT delivered QW improved acute bowel and urinary QOL compared to EOD. Patients should be counselled regarding the potential for reduced short-term toxicity and improved QOL with QW prostate SBRT.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Miralbell R.
        • Roberts S.A.
        • Zubizarreta E.
        • Hendry J.H.
        Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9–2.2) Gy.
        Int J Radiat Oncol Biol Phys. 2012; 82: e17-e24
        • Dearnaley D.
        • Syndikus I.
        • Mossop H.
        • Khoo V.
        • Birtle A.
        • Bloomfield D.
        • et al.
        Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
        Lancet Oncol. 2016; 17: 1047-1060
        • Lee W.R.
        • Dignam J.J.
        • Amin M.B.
        • Bruner D.W.
        • Low D.
        • Swanson G.P.
        • et al.
        Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer.
        J Clin Oncol. 2016; 34: 2325-2332
        • Catton C.
        • Lukka H.
        • Julian J.
        • Gu C.
        • Martin J.
        • Supiot S.
        • et al.
        A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer.
        J Clin Oncol. 2016; 34: Abstr 5003
        • Loblaw A.
        • Cheung P.
        • D’Alimonte L.
        • Deabreu A.
        • Mamedov A.
        • Zhang L.
        • et al.
        Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes.
        Radiother Oncol. 2013; 107: 153-158
        • King C.R.
        • Freeman D.
        • Kaplan I.
        • Fuller D.
        • Bolzicco G.
        • Collins S.
        • et al.
        Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials.
        Radiother Oncol. 2013; 109: 217-221
        • Evans J.R.
        • Zhao S.
        • Daignault S.
        • Sanda M.G.
        • Michalski J.
        • Sandler H.M.
        • et al.
        Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
        Radiother Oncol. 2015; 116: 179-184
        • Katz A.J.
        • Santoro M.
        • Ashley R.
        • Diblasio F.
        • Witten M.
        Stereotactic body radiotherapy for organ-confined prostate cancer.
        BMC Urol. 2010; 10
        • Boike T.P.
        • Lotan Y.
        • Cho L.C.
        • Brindle J.
        • DeRose P.
        • Xie X.J.
        • et al.
        Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.
        J Clin Oncol. 2011; 29: 2020-2026
        • Thames H.D.
        • Kuban D.
        • Levy L.B.
        • Horwitz E.M.
        • Kupelian P.
        • Martinez A.
        • et al.
        The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
        Radiother Oncol. 2010; 96: 6-12
        • King C.R.
        • Brooks J.D.
        • Gill H.
        • Pawlicki T.
        • Cotrutz C.
        • Presti Jr., J.C.
        Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
        Int J Radiat Oncol Biol Phys. 2009; 73: 1043-1048
        • Wei J.T.
        • Dunn R.L.
        • Litwin M.S.
        • Sandler H.M.
        • Sanda M.G.
        Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
        Urology. 2000; 56: 899-905
        • Cox J.D.
        • Stetz J.
        • Pajak T.F.
        Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC).
        Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346
        • Storey M.R.
        • Pollack A.
        • Zagars G.
        • Smith L.
        • Antolak J.
        • Rosen I.
        Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial.
        Int J Radiat Oncol Biol Phys. 2000; 48: 635-642
        • Roach 3rd, M.
        • Hanks G.
        • Thames Jr., H.
        • Schellhammer P.
        • Shipley W.U.
        • Sokol G.H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Norman G.R.
        • Sloan J.A.
        • Wyrwich K.W.
        Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.
        Med Care. 2003; 41: 582-592
        • Aluwini S.
        • Pos F.
        • Schimmel E.
        • Krol S.
        • van der Toorn P.P.
        • de Jager H.
        • et al.
        Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
        Lancet Oncol. 2016; 17: 464-474
        • Musunuru H.B.
        • Quon H.
        • Davidson M.
        • Cheung P.
        • Zhang L.
        • D'Alimonte L.
        • et al.
        Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.
        Radiother Oncol. 2016; 118: 112-117
        • Quon H.C.
        • Musunuru H.B.
        • Cheung P.
        • Pang G.
        • Mamedov A.
        • D'Alimonte L.
        • et al.
        Dose-escalated stereotactic body radiation therapy for prostate cancer: quality-of-life comparison of two prospective trials.
        Front Oncol. 2016; 6: 185
        • King C.R.
        • Brooks J.D.
        • Gill H.
        • Presti Jr., J.C.
        Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2012; 82: 877-882
        • Evans J.R.
        • Zhao S.
        • Daignault S.
        • Sanda M.G.
        • Michalski J.
        • Sandler H.M.
        • et al.
        Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
        Radiother Oncol. 2015; 116: 179-184
        • King C.R.
        • Collins S.
        • Fuller D.
        • Wang P.C.
        • Kupelian P.
        • Steinberg M.
        • et al.
        Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
        Int J Radiat Oncol Biol Phys. 2013; 87: 939-945
        • Tucker S.L.
        • Thames H.D.
        • Michalski J.M.
        • Bosch W.R.
        • Mohan R.
        • Winter K.
        • et al.
        Estimation of alpha/beta for late rectal toxicity based on RTOG 94–06.
        Int J Radiat Oncol Biol Phys. 2011; 81: 600-605
        • Meier R.
        • Beckman A.
        • Henning G.
        • Mohideen N.
        • Woodhouse S.A.
        • Cotrutz C.
        • et al.
        Five-Year Outcomes From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.
        Int J Radiat Oncol Biol Phys. 2016; 96: S33-S34
        • Yeoh E.E.
        • Fraser R.J.
        • McGowan R.E.
        • Botten R.J.
        • Di Matteo A.C.
        • Roos D.E.
        • et al.
        Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
        Int J Radiat Oncol Biol Phys. 2003; 55: 943-955
        • Kim D.W.
        • Cho L.C.
        • Straka C.
        • Christie A.
        • Lotan Y.
        • Pistenmaa D.
        • et al.
        Predictors of rectal tolerance observed in a dose-escalated phase 1–2 trial of stereotactic body radiation therapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2014; 89: 509-517
        • Elias E.
        • Helou J.
        • Zhang L.
        • Cheung P.
        • Deabreu A.
        • D'Alimonte L.
        • et al.
        Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.
        Radiother Oncol. 2014; 112: 83-88
        • Mariados N.
        • Sylvester J.
        • Shah D.
        • Karsh L.
        • Hudes R.
        • Beyer D.
        • et al.
        Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy.
        Int J Radiat Oncol Biol Phys. 2015; 92: 971-977